Genmab — Juni 2017
-
Vurderet på baggrund af Genmabs meddelelse omkring Humax-TF er jeg ikke helt sikker på stoffets fremtid. Genmab vil nu nøje vurdere det kommercielle potentiale før de bringer stoffet videre i senfase forsøg. Her tænker jeg bl.a. på at div. vacciner til unge piger vil få antallet af cancertilfælde til at falde betydeligt.
-
-
-
Solsen: Mr Winkel. Could you sheed some light on when to expect Seattle Geneticts to decide to co-develope or let Genmab going alone on royalty basis with Tisotumab ?
Winkel: Contractually Seattle Genetics can exercise their opt in right at the end of the Phase 1/2 study. This study is ongoing..
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind